Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Sales and Divestitures (2023 - 2025)

Maxcyte has reported Gains from Sales and Divestitures over the past 3 years, most recently at $609460.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 45.71% to $609460.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $609460.0 through Dec 2025, up 45.71% year-over-year, with the annual reading at $609460.0 for FY2025, 45.71% up from the prior year.
  • Gains from Sales and Divestitures was $609460.0 for Q4 2025 at Maxcyte, up from $418260.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $609460.0 in Q4 2025 and troughed at $288550.0 in Q4 2023.
  • The 3-year median for Gains from Sales and Divestitures is $418260.0 (2024), against an average of $438756.7.
  • Year-over-year, Gains from Sales and Divestitures soared 44.95% in 2024 and then soared 45.71% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $288550.0 in 2023, then soared by 44.95% to $418260.0 in 2024, then surged by 45.71% to $609460.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Gains from Sales and Divestitures are $609460.0 (Q4 2025), $418260.0 (Q4 2024), and $288550.0 (Q4 2023).